Analysts forecast that Aileron Therapeutics Inc (NASDAQ:ALRN) will announce earnings of ($0.58) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.65). Aileron Therapeutics posted earnings of ($0.43) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 34.9%. The business is scheduled to issue its next earnings results on Thursday, November 8th.

On average, analysts expect that Aileron Therapeutics will report full-year earnings of ($2.16) per share for the current financial year, with EPS estimates ranging from ($2.37) to ($1.95). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.15) per share, with EPS estimates ranging from ($2.71) to ($1.63). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04).

ALRN has been the topic of several research reports. Zacks Investment Research upgraded shares of Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Tuesday, July 10th. ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.

In other news, major shareholder Bioventures Ltd Novartis sold 31,300 shares of the stock in a transaction on Tuesday, July 24th. The shares were sold at an average price of $4.25, for a total transaction of $133,025.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Apple Tree Partners Ii Lp sold 9,532 shares of the stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $5.32, for a total transaction of $50,710.24. The disclosure for this sale can be found here. In the last quarter, insiders acquired 6,000 shares of company stock worth $32,290 and sold 242,150 shares worth $1,223,406. 16.10% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in Aileron Therapeutics stock. Millennium Management LLC purchased a new position in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,585 shares of the company’s stock, valued at approximately $151,000. Millennium Management LLC owned about 0.13% of Aileron Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.79% of the company’s stock.

Aileron Therapeutics stock remained flat at $$2.44 during trading hours on Tuesday. 59,896 shares of the company’s stock traded hands, compared to its average volume of 75,383. The company has a current ratio of 5.85, a quick ratio of 9.16 and a debt-to-equity ratio of 0.10. Aileron Therapeutics has a 1 year low of $2.18 and a 1 year high of $15.48.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.